

Psilocybin Informed Consent

Adopted: 4-6-2026

Before undergoing psilocybin-assisted therapy, informed consent must be obtained from both the facilitator and patient. Informed consent should be obtained through direct discussion and shall not be solely satisfied by written acknowledgement. The discussion shall include risks, benefits, uncertainties, altered states of consciousness, and impaired decision making.

Must also disclose and receive consent decisions related to safety planning, physical touch, the presence of other individuals, the process and nature of termination services.

Patient and facilitator should discuss supportive, non sexual, touch. For instance, hands, shoulders, and feet are generally appropriate. Patients and facilitators retain the right to withdraw their consent for supportive touch at any time during the session.

The Department shall create a standardized informed consent form, notifying the patient what psilocybin is, overview of psilocybin treatment, possible side/adverse effects associated with treatment, benefits of psilocybin use, and a statement acknowledging that the use of psilocybin has not been approved by the FDA to treat or cure any condition.